Dermata Therapeutics, Inc. (DRMA)
NASDAQ: DRMA · Real-Time Price · USD
1.250
+0.040 (3.31%)
At close: Feb 21, 2025, 4:00 PM
1.230
-0.020 (-1.60%)
After-hours: Feb 21, 2025, 6:27 PM EST
Dermata Therapeutics Employees
Dermata Therapeutics had 8 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,408,812
Market Cap
2.55M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 1 | 14.29% |
| Dec 31, 2020 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
DRMA News
- 24 days ago - Dermata to Present on BioPub on January 31, 2025 - Accesswire
- 25 days ago - Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment - Accesswire
- 4 weeks ago - Dermata Therapeutics Announces Closing of $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Accesswire
- 4 weeks ago - Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules - Accesswire
- 4 weeks ago - Dermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R) - Accesswire
- 2 months ago - Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM) - Accesswire
- 2 months ago - Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne - Accesswire
- 2 months ago - Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne - Accesswire